MCKESSON CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 518.8 USD | -1.35% |
|
-0.87% | +12.06% |
| Apr. 18 | Nephron Research Raises McKesson's Price Target to $600 From $530 | MT |
| Apr. 15 | Morgan Stanley Adjusts Price Target on McKesson to $548 From $522 | MT |
Financials (USD)
| Sales 2024 * | 312B | Sales 2025 * | 337B | Capitalization | 69.11B |
|---|---|---|---|---|---|
| Net income 2024 * | 3.03B | Net income 2025 * | 3.52B | EV / Sales 2024 * | 0.23 x |
| Net Debt 2024 * | 1.78B | Net Debt 2025 * | 375M | EV / Sales 2025 * | 0.21 x |
| P/E ratio 2024 * |
23.9
x | P/E ratio 2025 * |
19
x | Employees | 48,000 |
| Yield 2024 * |
0.46% | Yield 2025 * |
0.51% | Free-Float | 46.58% |
More Fundamentals
* Assessed data
More news
Latest transcript on McKesson Corporation
More recommendations
More press releases
| 1 day | -1.35% | ||
| 1 week | -0.87% | ||
| Current month | -3.36% | ||
| 1 month | -2.06% | ||
| 3 months | +5.24% | ||
| 6 months | +13.84% | ||
| Current year | +12.06% |
1 week
514.88
532.00
1 month
514.88543.00
Current year
462.70543.00
1 year
352.34543.00
3 years
180.42543.00
5 years
111.90543.00
10 years
106.11543.00
| Managers | Title | Age | Since |
|---|---|---|---|
Brian Tyler
CEO | Chief Executive Officer | 57 | 11-12-31 |
| Director of Finance/CFO | 55 | 18-01-26 | |
Francisco Fraga
CTO | Chief Tech/Sci/R&D Officer | 51 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Donald Knauss
CHM | Chairman | 73 | 14-10-19 |
Webster Dunbar
BRD | Director/Board Member | 62 | 22-03-31 |
| Director/Board Member | 66 | 22-01-12 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.31% | 1,026 M€ | +6.11% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 518.8 | -1.35% | 631,440 |
| 24-04-17 | 525.9 | -0.46% | 538,003 |
| 24-04-16 | 528.4 | +1.08% | 362,609 |
| 24-04-15 | 522.7 | -0.06% | 372,220 |
| 24-04-12 | 523 | -0.07% | 484,479 |
Delayed Quote Nyse, April 18, 2024 at 04:00 pm EDT
More quotes
McKesson Corporation specializes in pharmaceutical product distribution. The group also offers technological services to healthcare companies. Net sales break down by activity as follows:
- distribution of pharmaceutical products (87%);
- distribution of medical and surgical products (4%);
- other (1.6%): primarily technology services and software sales.
The remaining net sales (7.4%) are from international activities.
Sector
Pharmaceuticals
Calendar
2024-05-07
- Q4 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
525.9
USD
Average target price
559.5
USD
Spread / Average Target
+6.39%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.06% | 69.11B | |
| +5.16% | 25.91B | |
| +4.48% | 8.01B | |
| -3.28% | 7.91B | |
| -23.97% | 7.27B | |
| -0.67% | 4.51B | |
| +20.68% | 4.48B | |
| -4.23% | 3.95B | |
| -3.99% | 3.79B | |
| +23.62% | 3.7B |
- Stock Market
- Equities
- MCK Stock
